pregnancy; maternal adverse events; antipsychotics; fetotoxicity; effectiveness; epidemiology
Panchaud Alice, Cohen Jacqueline M., Patorno Elisabetta, Huybrechts Krista F., Desai Rishi J., Gray Kathryn J., Mogun Helen, Hernandez-Diaz Sonia, Bateman Brian T. (2018), Anticonvulsants and the risk of perinatal bleeding complicationsA pregnancy cohort study, in Neurology
, 91(6), e533-e542.
Collin-Lévesque Laurence, El-Ghaddaf Yosra, Genest Madeleine, Jutras Martin, Leclair Grégoire, Weisskopf Etienne, Panchaud Alice, Ferreira Ema (2018), Infant Exposure to Methylphenidate and Duloxetine During Lactation, in Breastfeeding Medicine
, 13(3), 221-225.
Panchaud Alice, Rousson Valentin, Vial Thierry, Bernard Nathalie, Baud David, Amar Emmanuelle, De Santis Marco, Pistelli Alessandra, Dautriche Anne, Beau-Salinas Frederique, Cassina Matteo, Dunstan Hannah, Passier Anneke, Kaplan Yusuf Cem, Duman Mine Kadioglu, Maňáková Eva, Eleftheriou Georgios, Klinger Gil, Winterfeld Ursula, Rothuizen Laura E., Buclin Thierry, Csajka Chantal, Hernandez-Diaz Sonia (2018), Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information servicesPregnancy outcomes in women on metformin in early pregnancy, in British Journal of Clinical Pharmacology
, 84(3), 568-578.
Panchaud A Hernandez-Diaz S Freeman MP Viguera AC MacDonald SC Sosinsky AZ Cohen LS (2017), Use of atypical antipsychotics in pregnancy and maternal gestational diabetes., in J Psychiatr Res
, 95, 84-90.
Patorno E Bateman BT Huybrechts KF MacDonald SC Cohen JM Desai RJ Panchaud A Mogun H Pennell (2017), Pregabalin use early in pregnancy and the risk of major congenital malformations., in Neurology
, 88(21), 2020-2025.
Panchaud A Stojanov M Ammerdorffer A Vouga M Baud D. (2016), Emerging Role of Zika Virus in Adverse Fetal and Neonatal Outcomes., in Clinical microbiology Review
1. A. Panchaud M. Vouga D. Musso D. Baud, An international registry for women exposed to zika virus during pregnancy: time for answers., in Lancet Infectious Disease
K.F. Huybrechts S. Hernandez-Diaz E. Patorno R.J. Desai H. Mogun S.Z. Dejene, J. Cohen, , A. Panchaud L. Cohen B. T. Bateman., Antipsychotic Medication Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study., in JAMA psychiatry
Psychiatric disorders are among the leading causes of ill-health and disability in Western societies (WHO website) with an onset in women usually before and during the childbearing years. Atypical antipsychotic medications (second generation) have over time increasingly being used to treat a spectrum of psychiatric disorders, including psychotic disorders and bipolar disorder, as well as treatment of refractory depression and anxiety disorders. Since pregnant women are typically excluded from clinical trials, most information regarding the safety/risk profile of drugs during pregnancy is collected after the drug has been approved and used by pregnant women intentionally or unintentionally (e.g. conditions require treatment or unplanned pregnancy), using pharmaco-epidemiology methodology. Even though the number and proportion of pregnancies exposed to atypical antipsychotics has increased dramatically in recent years, the effectiveness and safety of antipsychotics agents in pregnant populations is largely unknown. This research project aims at comparing the safety and effectiveness of different atypical antipsychotics, given as mono or polytherapy, during pregnancy for the fetus and the mother using two large data sets (National Pregnancy Registry for Atypical Antipsychotics & Medicaid Analytic eXtract (MAX)) in order to answer the clinically relevant questions: 1) which specific atypical antipsychotic to recommend for women of childbearing age, 2) whether and when to discontinue treatment during pregnancy.